← All trials
NCT06158386
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 22, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Dec 6, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 33
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xiamen UniversityLead sponsor
- Nanjing Medical UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Xiamen UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Huizhou People's Central HospitalCollaborator
- Fujian Provincial HospitalCollaborator
- Jieyang People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.